TCT Conference 24 - Two-year outcomes of CLASP IID shows that the Edwards PASCAL system was noninferior to the Abbott Mitraclip system in transcatheter mitral valve repair for mitral regurgitation.

Dr Firas Zahr (Oregon Health and Science University, US) joins us onsite at TCT Conference to discuss the outcomes from the CLASP IID 2 Year RCT and Registry (NCT02371512; Edwards Lifesciences).

CLASP IID 2 is a multicenter, randomised, controlled trial investigating the use of the Edwards PASCAL system for transcatheter mitral edge-to-edge repair (TEER) in patients with moderate-to-severe mitral regurgitation (MR). 300 patients were enrolled in the study and were followed-up at discharge, 30 days, 6 months, and annually through 5 years.

Two-year findings showed the Edwards PASCAL system demonstrated favorable survival rates with significant and consistent improvements in functional status and quality of life for MR patients, sustained MR reduction, and significant and durable ventricular remodeling.

Interview Questions:
1.    What is the reasoning behind this study?
2.    What was the study design and patient population?
3.    What were the key findings?
4.     Were there any surprising or unexpected results?
5.    What further research is needed, and what are the next steps?

Recorded on-site at TCT Conference in Washington, 24

Editors: Yazmin Sadik, Jordan Rance
Videographers:

Support: This is an independent interview produced by Radcliffe Cardiology.